ClinicalTrials.gg

Program

ABBV-7828

A development code.

In AbbVie's pipeline, JAK1i. Its studies are led by AbbVie.

Furthest: phase 1, since Sep 28, 20261 company-led study, 1 open or runningNext primary completion: May 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 1since Sep 28, 2026Sep 28, 2026May 2027phase 1 · NCT07856706
  • Named in AbbVie’s own pipeline as ABBV-7828, phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2026First study: phase 1 study in Healthy SubjectsFirst studyNCT07856706 · 60 planned · United States

Ahead

  1. May 2027Primary completion: phase 1 study in Healthy SubjectsNCT07856706

TargetBeta

“JAK1i”the company's pipeline, read by Claude · source

Other programs on JAK1

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
baricitinibruleEli Lillyphase 459
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 331
abrocitinibrulePfizerphase 330
ivarmacitinibruleJiangsu HengRui Medicinephase 325
brepocitinibrulePfizerphase 325
delgocitinibruleLEO Pharmaphase 321
momelotinibruleGlaxoSmithKlinephase 317

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07856706Healthy Subjects · United States1RecruitingMay 202760

How it is read

Names in the registry

  • “ABBV-7828”, 1 entry

Codes read as this program: ABBV7828.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.